has function has role immunizes against disease immunizes recipient urinary bladder cancer Homo sapiens recombinant vector vaccine therapeutic vaccine function vaccine in clinical trial role recombinant vector vaccine role bladder cancer vaccine gp96-secreting Allogeneic Bladder Cancer Cell Vaccine HS-410 7184 5033 Yuanyi (Penny) Pan https://github.com/vaccineontology/VO/issues/209 An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of the gp96-Ig-secreting allogeneic bladder cancer cell vaccine HS-410, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells. Justin Song VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5033 cancer vaccine Jie Zheng Oliver He Gene name: HSP90B1 therapeutic cancer vaccine